Genomics, diagnostics push HTEC ETF gains through July 3

The ROBO Global Healthcare Technology and Innovation Index rose through July 3, 2026, driven by gains in genomics and diagnostics. Twist Bioscience climbed 212.9%, Moderna rose 170.5% and Guardant Health gained 64.5% over the period.

Those three stocks provided the largest lifts to returns for the HTEC exchange-traded fund. Twist contributed 2.8 percentage points to total index performance, Moderna added 1.9 percentage points and Guardant contributed 1.4 percentage points for the period ending July 3.

The HTEC ETF follows the ROBO Global Healthcare Technology and Innovation Index, which groups companies across nine healthcare categories: precision medicine, medical instruments, genomics, process automation, diagnostics, robotics, regenerative medicine, telehealth and data analytics.

Performance through July 3 was led by diagnostic and genomic businesses. The gains were concentrated among a small number of high-growth companies rather than spread evenly across the index. Smaller developers of medical tools and firms working on liquid biopsy technologies were among the notable performers.

Traditional cap-weighted healthcare funds typically allocate more to large pharmaceutical companies and can leave investors underexposed to specialized medical-technology firms. HTEC’s strategy provides targeted exposure across the healthcare technology value chain, including diagnostics, genomics and lab automation.

VettaFi LLC maintains the index and receives an index licensing fee. HTEC is not issued, sponsored or endorsed by VettaFi.